Almirall enters partnership with Inserm Transfert to research vitiligo

A partnership between the Spanish biotech firm and the private subsidy of French public research organization Inserm will focus on finding treatment options for the chronic skin condition vitiligo.

Photo: Mikkel Aabenhus Hemmingsen / MedWatch

Spanish skin health firm Almirall has entered a licensing and research collaboration with Inserm Transfers, a private subsidiary of Inserm, which is the French National Institute of the Health and Medical Research, the company reports in a press release.

Together, they will collaborate to advance treatment options for the chronic repigmentation skin condition, vitiligo, with the hope to develop a new class of drugs targeting the Wnt pathway, which is involved in skin repigmentation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs